Remove 2025 Remove Innovation Remove Patient Care
article thumbnail

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

DAIC

mtaschetta-millane Mon, 07/29/2024 - 09:02 July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth.

article thumbnail

Primary Prevention Takes Center Stage at the 19th Annual Cardiometabolic Health Congress (CMHC)

Cardiometabolic Health Congress

The Hilton Boston Park Plaza became a hub of innovation, education, and collaboration, uniting nearly 500 clinicians under a shared mission: to redefine cardiometabolic care. The 19th Annual CMHC was more than just CME/CE medical education—it ignited global collaboration and inspired groundbreaking innovations.

CME 64
article thumbnail

ACC Clinical Trials Research Program REACH(es) New Heights

DAIC

Getty Images milla1cf Tue, 03/19/2024 - 19:09 March 19, 2024 — The American College of Cardiology ( ACC ) has selected 50 learners for its 2024 – 2025 Clinical Trials Research (CTR) program , of whom 28 structural heart cardiologists and surgeons will participate in the CTR’s new Project REACH.

Research 105
article thumbnail

Endotronix Receives FDA Premarket Approval of the Cordella PA Sensor System for the Treatment of Heart Failure

DAIC

Cordella is a proactive HF management platform that delivers daily PA pressure and other vital data via an implantable sensor and user-friendly, non-invasive health tools, respectively, to a managing HF clinician for remote patient care. Reimbursement for implantation and ongoing management through existing reimbursement pathways. "At